

Express Mail Label No.: EV399525163US
Date of Deposit: March 14, 2005

1 of 1

/ Please type a plus sign (+) in this box ☐



PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/692,523
	Filing Date	10/24/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-501 CIP4

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
cm	A10	6,451,334	09/17/02	Perrine			04/30/01
cm	A11	2003/0161830	08/28/03	Jackson et al.			06/14/02
cm	A12	2004/0127523	07/01/04	Bacopoulos et al.			09/16/03

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No


NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
cm	C56	International Search Report for PCT/US03/06451, mailed October 27, 2003
	C57	International Preliminary Examination Report for PCT/US03/06451, mailed August 3, 2004
	C58	International Search Report for PCT/US04/27943, mailed March 7, 2005
	C59	Wu et al. (2001). "Negative Regulation of bcl-2 Expression by p53 in Hematopoietic Cells." <i>Oncogene</i> 20(2): 240-251, Abstract, Database CAPLUS on STN, Acc. No. DN134:293668.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	9-19-05
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYC 316145v1



Express Mail Label No.: EV399525764US

Date of Deposit: April 6, 2004

Page 1 of 3

Please type a plus sign (+) in this box



PTO/SB (12-97)

OMB 0631-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/692,523
	Filing Date	10/24/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-501 CIP4

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
C11	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3*	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8*	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00


FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
C11	B1*	WO	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X
	B2*	WO	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X
	B3*	WO	00/71703	Methylgene, Inc.	November 30, 2000	X
	B4*	WO	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X
	B5*	WO	01/38322	Methylgene, Inc.	May 31, 2001	X
	B6*	WO	01/70675	Methylgene, Inc.	September 27, 2001	X
	B7*	WO	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X
	B8*	WO	02/30879	Prolifix Limited	April 18, 2002	X
	B9*	WO	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C11	C1*	Andrews et al. (2000). <i>Intl. J. Parasitol.</i> 30: 761-768.
	C2*	Archer et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 6791-6796.
	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology, 44th Meeting of the American Society of Hematology, Abstract 4611.</i>
	C4*	Butler et al. (2000). <i>Cancer Res.</i> 60: 5165-5170.
	C5*	Butler et al. (2001). <i>Clinical Cancer Res.</i> 7: 962-970.
	C6*	Butler et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> 99: 11700-11705.
	C7*	Coffey et al. (2000). <i>Medical and Pediatric Oncology</i> 35: 577-581.


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
um	C8*	Coffey et al. (2001). <i>Cancer Res.</i> 61: 3591-3594.
	C9*	Cohen et al. (1999). <i>Anticancer Res.</i> 19: 4999-5006.
	C10*	Cohen et al. (2002). <i>Anticancer Res.</i> 22: 1497-1504.
	C11*	Curtin (2002). <i>Exp. Opin. Ther. Patents</i> 12: 1375-1384.
	C12*	Dressel (2000). <i>Anticancer Res.</i> 20: 1017-1022.
	C13*	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology Abstract No. 4602.
	C14*	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract No. 3195.
	C15*	Finnin et al. (1999). <i>Nature</i> 401: 188-193.
	C16*	Furamai et al. (2001). <i>Proc. Natl. Sci. USA</i> 98: 87-92.
	C17*	Grunstein (1997). <i>Nature</i> 389: 349-352.
	C18*	He et al. (2001). <i>J. Clin. Investigation</i> 108: 1321-1330.
	C19*	Hockly et al. (2003). <i>Proc. Natl. Acad. Sci. USA</i> 100: 2041-2046.
	C20*	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." <i>American Society of Clinical Oncology</i> , Abstract No. 344.
	C21*	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.
	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> 38(Suppl. 7): 88, Abstract No. 286.
	C23*	Kim et al. (1999). <i>Oncogene</i> 18: 2461-2470.
	C24*	Kohge et al. (1998). <i>Biochem. Pharmacol.</i> 56: 1359-1364.
	C25*	Komatsu et al. (2001). <i>Cancer Res.</i> 61: 4459-4466.
	C26*	Kouraklis and Theocharis (2002). <i>Curr. Med. Chem. Anti-Cancer Agents</i> 2: 477-484.
	C27*	Lee et al. (2001). <i>Cancer Res.</i> 61: 931-934.
	C28*	Lin et al. (1998). <i>Nature</i> 391: 811-814.
	C29*	Mai et al. (2001). <i>OPPI Briefs</i> 33: 391-394
	C30*	Marks et al. (2000). <i>J. of the Natl. Cancer Institute</i> 92: 1210-1215.
	C31*	Marks et al. (2001). <i>Clinical Cancer Res.</i> 7: 759-760.
	C32*	Marks et al. (2001). <i>Curr. Opin. In Oncology</i> 13: 477-483.
	C33*	Marks et al. (2001). <i>Nature Reviews</i> 1: 194-202.
	C34*	Miller et al. (2003). <i>J Med Chem.</i> 46: 5097-5116.
	C35*	Munster et al. (2001). <i>Cancer Res.</i> 61: 8492-8497.
	C36*	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742.
	C37*	Qui et al. (2000). <i>Mol. Biol. Cell</i> 11: 2069-2083.
	C38*	Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> 93: 5705-5708.
	C39*	Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 3003-3007.
	C40*	Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97: 10014-10019.
	C41*	Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> 8: 662-664.
	C42*	Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> 96: 4592-4597.
	C43*	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C44*		Radiation in Human Prostate Tumor Spheroids." <i>American Society of Clinical Oncology</i> , Abstract No. 105.
	C44*	Stowell et al. (1995). <i>J. Med. Chem.</i> 38: 1411-1413.
	C45*	Su et al. (2000). <i>Cancer Res.</i> 60: 3137-3142.
	C46*	Suzuki et al. (1999). <i>J. Med. Chem.</i> 42: 3001-3003.
	C47*	Van Lint et al. (1996). <i>Gene Expression</i> 5: 245-253.
	C48*	Vrana et al. (1999). <i>Oncogene</i> 18: 7016-7025.
	C49*	Webb et al. (1999). <i>J. Biol. Chem.</i> 274: 14280-14287.
	C50*	Yoshida et al. (1990). <i>J. Biol. Chem.</i> 265: 17174-17179.
	C51*	Yoshida et al. (1995). <i>BioEssays</i> 17: 423-430.
	C52*	Zhou et al. (1999). <i>Gene</i> 233: 13-19.
	C53*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97: 1056-1061.
	C54*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97: 14329-14333.
	C55*	Zhou et al. (2001). <i>Proc. Natl. Acad. Sci. USA</i> 98: 10572-10577.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/379,149, filed March 4, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	9-19-05
--------------------	---	-----------------	---------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail Label No.: EV627295662US
Date of Deposit: June 9, 2005

PAGE 1 of 2

Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/692,523
	Filing Date	10/24/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-501 CIP4

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
cm	A13	6,231,880	05/15/2001	Perrine	424	423	05/29/1998
	A14	2004/0002506	12/30/2004	Breslow et al.	514	310	04/01/2004
	A15	2004/0087631	05/06/2004	Bacopoulos et al.	514	352	08/26/2003
	A16	2004/0122101	06/24/2004	Miller et al.	514	575	06/19/2003
	A17	2004/0127522	07/01/2004	Chiao et al.	514	352	07/09/2003
	A18	2004/0266818	01/01/2004	Breslow et al.	514	263.4	10/25/2002
	A19	2004/0072735	04/15/2004	Richon et al.	514	9	03/04/2003

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
cm	B10	WO 01/16106	Schering Aktiengesellschaft	03/08/2001	X

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
cm	C60	Adams and Elliott (2000). <i>Oncogene</i> <u>19</u> : 6687-6692.
	C61	Bates et al. (1999). <i>Proc. American Society of Clinical Oncology</i> <u>18</u> : 180a, Abstract No. 693
	C62	Foster et al. (1997). <i>Invest. New Drugs</i> <u>15</u> : 187-194.
	C63	Gojo et al. (2002). <i>Blood</i> <u>100</u> : Abstract No. 2198.
	C64	Gore and Carducci (2000). <i>Exp. Opin. Invest. Drugs</i> <u>9</u> : 2923-2934.
	C65	Huang and Pardee (2000). <i>Molecular Medicine</i> <u>6</u> : 849-866.
	C66	Johnstone, R. (2002). <i>Nature Reviews Drug Discovery</i> <u>1</u> : 287-299.
	C67	Kelly et al. (2002). <i>Exp. Opin. Invest. Drugs</i> <u>11</u> : 1695-1713.
	C68	Kelly et al. (2002). <i>Proc. American Society of Clinical Oncology</i> <u>21</u> : 6b, Abstract No. 1831.
	C69	Kelly et al. (2001). <i>Proc. American Society of Clinical Oncology</i> <u>20</u> : 87a, Abstract No. 344.
	C70	Kosugi et al. (2001). <i>Jpn. J. Cancer Res.</i> <u>92</u> : 529-536.
	C71	Marshall et al. (2002). <i>J. Exp. Therapeutics and Oncology</i> <u>2</u> : 325-332.
	C72	Piekarz et al. (2001). <i>Blood</i> <u>98</u> : 2865-2868.

Date of Deposit: June 9, 2005



NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
CPM	C73	Prakash et al. (2001). <i>Invest. New Drugs</i> <u>19</u> : 1-11.
	C74	Rha et al. (1993). <i>J. Korean Med. Sci.</i> <u>8</u> :251-256.
	C75	Rifkind et al. (2002). <i>224th ACS National Meeting, Boston, MA</i> , Abstract No. 226.
	C76	Sandor et al. (2002). <i>Clinical Cancer Research</i> <u>8</u> : 718-728.
	C77	Secrist et al. (2003). <i>Curr. Opin. Invest. Drugs</i> <u>4</u> :1422-1427.
	C78	Summerhayes, M. (2001). <i>J. Oncol. Pharm. Prac.</i> <u>7</u> : 107-125.
	C79	Vigushin, D. (2002). <i>Current Opin. Invest. Drugs</i> <u>3</u> : 1396-1402.
	C80	Warrell et al. (1998). <i>J. Natl. Cancer Institute</i> <u>90</u> : 1621-1625.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	CPM	Date Considered	9-19-05
--------------------	-----	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.